Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

By Adamson P.   Blaney S.   Widemann B.   Kitchen B.   Murphy R.   Hannah A.   Cropp G.   Patel M.   Gillespie A.   Whitcomb P.   Balis F.M.  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 482-488

Springer Publishing Company

Access to resources Recommend Favorite

Angiogenesis in primary central nervous system lymphoma (PCNSL)

By Takeuchi Hiroaki   Matsuda Ken   Kitai Ryuhei   Sato Kazufumi   Kubota Toshihiko  

Journal of Neuro-Oncology, Vol. 84, Iss. 2, 2007-09 ,pp. : 141-145

Springer Publishing Company

Access to resources Recommend Favorite

Diagnostic delay in primary central nervous system lymphoma

By Haldorsen Ingfrid S.   Espeland Ansgar   Larsen John Ludvig   Mella Olav  

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 728-734

Informa Healthcare

Access to resources Recommend Favorite

Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-α, -β, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy

By Haberler C.   Gelpi E.   Marosi C.   Rössler K.   Birner P.   Budka H.   Hainfellner J.  

Journal of Neuro-Oncology, Vol. 76, Iss. 2, 2006-01 ,pp. : 105-109

Springer Publishing Company

Access to resources Recommend Favorite

Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma

By Kitai Ryuhei  

Brain Tumor Pathology, Vol. 30, Iss. 1, 2013-01 ,pp. : 34-39

Springer Publishing Company

Access to resources Recommend Favorite